Expanding indications for liver transplantation in the era of liver transplant oncology

Table 1 Liver transplant selection criteria for hepatocellular carcinoma

Reference	Criteria	Definition	OS	Recurrence
Mazzaferro et al[22]	Milan criteria	Solitary tumor ≤ 5 cm or total ≤ 3 tumors and each tumor ≤ 3 cm	4-yr 75%	4-yr RFS 83%
Yao et al[24]	UCSF criteria	Solitary tumor ≤ 6.5 cm or total ≤ 3 nodules with the largest lesion ≤ 4.5 cm and total tumor diameter ≤ 8 cm	5-yr 75.2%	5-yr RR: 17%
Takada et al[27]	Kyoto criteria	Tumor number ≤ 10 and maximal diameter of each tumor ≤ 5 cm and serum des-gamma-carboxy prothrombin levels ≤ 400 mAU/mL	5-yr 87%	5-yr RR: 5%
Mazzaferro et al[26]	Up-to-Seven criteria	Sum of number of tumors ≤ 7 and maximal size of the largest tumor ≤ 7cm	5-yr 71.2%	5-yr RR: 9.1%

OS: Overall survival; RFS: Recurrence free survival; NR: Not reported; RR: Risk ratio.

Table 2 Clinical trials in transplantation vs best medical therapy for liver-limited colorectal metastases

Ref.	Study	n	Characteristics	Intervention	Overall survival	Progression free survival
Hagness et al[75]	SECA-I	21	Unresectable; > 6 mo of neoadjuvant therapy	Liver transplant	5-yr OS: 60%	5-yr RFS: 33%
Dueland et al[68]	SECA-II	15	Unresectable; at least a 10% response to systemic therapy; disease stability 12 mo	Liver transplant	5-yr OS: 83%	3-yr RFS: 35%
Tveit et al[76]	NORDIC VII	566	Metastatic CRC; treatment-naïve; no resection with curative intent	A: FLOX alone; B: FLOX + Cetuximab; C: Cetuximab + Intermittent FLOX	3-yr OS: 6-8%	1-yr PFS: 20-32%

OS: Overall survival; PFS: Progression free survival; RFS: Recurrence free survival; CRC: Colorectal cancer.